ABUS - agree that Sofia is not showing everything even if that includes something better in the works. If you blow up the graph I referred to in earlier post, there is an unlabeled median data point (bold circle) that suggest Sofia is working on core inhibitor better than AB-836. What is ENTA suggesting as combos to core inhibitor? IMCR's TCR seems the most unique but non-oral as you pointed out.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.